This audio is automatically generated. Do us know if you have comments.
Brief of diving:
- Novartis will substantially expand his north -American footprint, announced on Thursday, spending $ 23 billion for five years to build six new factories, expanding three existing ones and adding a new research and development center.
- The Swiss Medication Manufacturer said that his expansion will allow him to manufacture the entire medicine for North -American patients in the country, at a time when President Donald Trump’s fare policies have launched world negotiation plans for the crisis. Novartis follows Eli Lilly, Merck & Co. and Johnson & Johnson on publishing new capital expense initiatives as Trump Pressures Major Corporations to bring manufacturing in the United States
- The Novartis Plan seems to reverse some of the company’s recent interiors in the United States, including the closure of an R&D center in San Diego, the announced place of the new R&D site in the United States, and the stoppage of places in North Carolina, Colorado and Illinois. The company has revealed the closure of seven manufacturing places between 2021 and 2024.
Divide vision:
The expansion of Novartis will substantially increase its capital expense, which has resorted to about $ 1 billion in recent years. It will also expand the commercial footprint of Novartis, adding six new facilities to the 12 it already has. In the United States, it currently lists the headquarters of its subsidiary in New Jersey, a R&D center in Cambridge, Massachusetts and Plants in Indianapolis and New Jersey.
Novartis said he would build two new plants to make radio -ray -to -rays such as his medicines against Rain and Lutatera cancer in Florida and Texas, as well as expand existing plants in Indianapolis, Millburn, New Jersey and Carlsbad, California.
Places of four facilities have not yet been determined. Three will make substances, products, devices and biological packages, while the fourth will make chemicals of medicines, tablets and packaging.
Novartis is already trusting in the United States to make some of its most complex medicines, such as cellular and gene therapies. With the new investment, it will locate a bit of its manufacture of medicines with anti -Senine oligonucleotids in the United States for the first time.
Novartis will also establish a “Biomedical Research Innovation Center” of $ 1.1 billion in San Diego. This site will open between 2028 and 2029.
“These investments will allow us to fully bring our chain of key supply and technological platforms to the United States to support our U.S. growth perspectives,” said CEO Vàsimhan, in a statement.
He also said that the company is well positioned to adjust to commercial interruptions, saying that the executives “fully trust our 2025 orientation, medium-term sales growth and basic margin orientation of 40%+”.
Novartis is expected to publish the results of the first quarter of 2025 on April 29.
